Related Experiment Video

Updated: Aug 7, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 19, 2013

Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys"

Teresa Alonso-Gordoa1, María Laura García-Bermejo2, Enrique Grande3

  • 1Medical Oncology Department, The Ramón y Cajal Health Research Institute (IRYCIS), CIBERONC, Alcalá University, University Hospital Ramon y Cajal, 28034 Madrid, Spain. talonso@oncologiahrc.com.

International Journal of Molecular Sciences
|April 20, 2019
PubMed

Insights

Clear cell renal cell carcinoma (ccRCC) treatment advances with targeted therapies. Targeting vascular endothelial growth factor receptor (VEGFR) and other tyrosine kinases shows promise for advanced kidney cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Clear cell renal cell carcinoma (ccRCC) is a significant cause of cancer deaths in Europe.
  • Von Hippel Lindau (VHL) gene alterations in 50% of ccRCC patients lead to HIF accumulation and increased VEGFR expression, driving tumor angiogenesis.
  • Targeting angiogenesis represents a new paradigm for metastatic renal cancer treatment.

Purpose of the Study:

  • To review the central role of tyrosine kinases in kidney cancer biology.
  • To discuss the utility of targeting tyrosine kinases in renal cell carcinoma (RCC) therapy development.
  • To provide an overview of current and emerging targeted therapies for advanced RCC.

Main Methods:

  • Literature review of molecular biology in ccRCC.
  • Analysis of signaling pathways including VHL, HIF, VEGFR, PDGFR, Axl, and MET.
  • Evaluation of targeted therapies for advanced renal cell carcinoma.

Main Results:

  • VEGFR-targeted therapies have improved survival in advanced renal cancer.
  • Other tyrosine kinase pathways (PDGFR, Axl, MET) are crucial in RCC.
  • New drugs targeting these kinases show significant efficacy.

Conclusions:

  • Tyrosine kinase inhibitors are vital in developing targeted therapies for kidney cancer.
  • Targeting angiogenesis remains a key strategy despite the rise of immunotherapy.
  • Continued research into tyrosine kinase pathways offers new therapeutic avenues for RCC.
Keywords:
AxlFibroblast Growth factor Receptor (FGFR)Kidney cancerPlatelet Derived Growth Factor Receptor (PDGFR)Tyrosine kinaseTyrosine-Protein Kinase Met (MET)Vascular endothelial growth factor receptor (VEGFR)

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...